Growth Opportunities and Trends in the Trigeminal Neuralgia Treatment Market: Key Insights for 2025-2034
Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
What key factors are powering the surge in the market right now?
The market for trigeminal neuralgia treatment has seen robust growth in previous times. It is projected to enlarge from $0.68 billion in 2024 to $0.73 billion in 2025, with a compound annual growth rate (CAGR) of 7.1%. The historical growth is ascribed to factors such as the escalating occurrence of chronic illnesses, the proliferating incidences of neurological disorders, the rising prevalence of trigeminal neuralgia, an increased push for minimally invasive therapies, and the surging demand for minimally invasive surgical procedures.
How fast Is the market expected to grow, and what’s its future value?
The market for trigeminal neuralgia treatment is anticipated to witness significant growth in the upcoming years, reaching $0.95 billion by 2029 with a compound annual growth rate (CAGR) of 6.7%. This predicted growth can be associated with factors such as a heightened consciousness about trigeminal neuralgia among both the general public and health professionals, escalating numbers of trigeminal neuralgia cases, a growing elderly population, and enhanced healthcare spending, coupled with an augmented count of diagnosed cases. Major trends observed during this forecast period encompass progress in neuromodulation techniques, advancement in TENS technology, strides in medical research and innovation, the shift towards less invasive surgical methods, and the rise of digital health technologies.
Get your market report here!
What main drivers are fueling expansion in the market?
The growing frequency of neurological conditions is anticipated to bolster the expansion of the trigeminal neuralgia treatment market in the future. These neurological conditions impact the nervous system, encompassing the brain, spinal cord, and nerves. The escalating occurrence of these disorders can be credited to many factors, such as hereditary tendencies, infections, trauma, toxins, autoimmune reactions, and degeneration. Trigeminal neuralgia treatments assist neurological patients by alleviating intense facial discomfort, minimizing nerve inflammation, improving life quality, aiding in pain control, and thwarting additional neurological damage. For example, in April 2022, the Belgium-based non-profit organization, European Brain Council, reported that over 600 neurological diseases and nearly 300 psychiatric conditions affect millions worldwide, with 65 million suffering from epilepsy. In Europe, the number of people with dementia stands at 10.5 million, with projections suggesting an increase to 18.7 million by 2050. As such, the escalating frequency of neurological conditions is anticipated to stimulate the expansion of the trigeminal neuralgia treatment market.
What are the key segments defining the market?
The trigeminal neuralgia treatment market covered in this report is segmented –
1) By Treatment Type: Medications, Surgery, Other Treatment Types
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
3) By End-User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Other End-Users
Subsegments:
1) By Medications: Anticonvulsants, Muscle Relaxants, Antidepressants
2) By Surgery: Microvascular Decompression Surgery, Gamma Knife Radiosurgery, Rhizotomy
3) By Other Treatment Types: Nerve Blocks, Stereotactic Radiosurgery, Physical Therapy
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21307&type=smp
Who are the key players steering the development of the market?
Major companies operating in the trigeminal neuralgia treatment market are Aetna Inc., Thermo Fisher Scientific Inc., Novartis AG, Sandoz, Sun Pharmaceutical Industries Ltd., Apotex Inc., Lupin Limited, Taro Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Kriya Therapeutics, Convergence Pharmaceuticals Limited, Noema Pharma AG, Max Healthcare, Initiator Pharma AS, Coda Biotherapeutics Inc., Oxford Cannabinoid Technologies Holdings Plc, NanoVibronix, Biogen Idec, Shanghai SIMR Biotechnology Co. Ltd., Capnia Inc.
Which trends are expected to transform the market?
Dominant businesses in the trigeminal neuralgia treatment domain are concentrating on submitting investigational new drug (IND) applications to help earn regulatory approval and increase their presence in the market. An IND application involves a pharmaceutical firm seeking permission from regulatory bodies to commence human trials for a new drug, with an assessment of its safety, efficacy, and proper dosage to follow. For instance, in February 2022, the US-based government agency, the Food and Drug Administration (FDA) received an IND application from Noema Pharma, a Swiss clinical-stage biotechnology firm for the drug LibraTN to start a Phase 2b clinical trial of the mGluR5 inhibitor NOE-101 for trigeminal neuralgia (TN). The LibraTN experiment is a 24-week, multi-center, placebo-controlled trial aimed at evaluating the effectiveness and safety of NOE-101 in dealing with TN-related pain among adults, with findings expected to be presented in the first half of 2024. Additionally, the FDA has given basimglurant (NOE-101) fast track designation for its expedited development and review.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21307
Which regions are most influential in expanding the market?
North America was the largest region in the trigeminal neuralgia treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the trigeminal neuralgia treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Pregnancy Test Kits Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/pregnancy-test-kits-global-market-report
Ectopic Pregnancy Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/ectopic-pregnancy-global-market-report
Infertility Treatment Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/infertility-treatment-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
